The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.
March 8th 2023
Susan M. Domchek, MD, highlights key points related to her presentation on germline testing and breast cancer treatment.
February 24th 2023
Development of Seribantumab for NRG1+ Advanced Solid Tumors Put On Hold
Elevation Oncology is pausing development of the human anti–HER3 IgG2 monoclonal antibody seribantumab, along with the phase 2 CRESTONE trial investigating the agent, in patients with advanced solid tumors harboring NRG1 fusions.
Socioeconomic Factors Are Associated With Disparities in Germline Testing in Pancreatic Cancer
Daniel King, MD, PhD, discusses the results of an institutional review evaluating socioeconomic factors associated with disparities for germline genetic testing in patients with pancreatic adenocarcinoma, why germline testing is necessary for thi population, and how he is addressing gaps in germline testing in his own practice.
Mutation Status Drives PARP Inhibitor Investigation and Treatment in mCRPC
February 1st 2023Atish D. Choudhury, MD, PhD, discussed the significance of these trials within the metastatic castration-resistant prostate cancer treatment landscape, highlighted investigative PARP inhibitor combinations, and emphasized the need for further research in this area to determine which patients are most likely to benefit from certain therapies based on their molecular profiles.
Genetic Analysis Helps Maximize Clinical Benefit with PARP Inhibitors in BRCA+ Ovarian Cancer
January 17th 2023Saketh Guntupalli, MD, highlights data supporting PARP inhibitors as the standard-of-care frontline therapy, strategies for the management of PARP-related toxicities, and the importance of testing for HRD and BRCA status in patients with ovarian cancer.
AFM24 Plus Atezolizumab Shows Acceptable Safety, Early Activity in EGFR+ Solid Tumors
A doublet comprised of the bispecific innate cell engager AFM24 and atezolizumab had a tolerable safety profile and elicited responses in patients with advanced EGFR-expressing solid tumors.
Physicians Turn to Molecular Profiling to Drive Treatment Decisions in Endometrial Cancer
Ritu Salani, MD, MBA, discusses the continued evolution of molecular profiling in endometrial cancer, advances in immunotherapy for endometrial and cervical cancer, and ongoing research in gynecologic cancers.
Biomarker Testing Informs Individualized Diagnosis and Treatment of Low- to Intermediate-Risk AML
December 16th 2022Alexander E. Perl, MD, MS, discusses the implications of the updated ELN guidelines, how genetic testing guides treatment in this disease, and ongoing research investigating novel AML targets such as NPM1 mutations or KMT2A translocations.
Perspectives From the Frontline: What Is Happening on the Ground With NGS Testing in NSCLC?
November 28th 2022Benjamin P. Levy, MD; Bhuvana Ramkumar, MD; and Neil Morganstein, MD, discuss the challenges with tissue testing facing care teams, as well as multilevel hurdles in procurement, analysis of results, and insurance.
FDA Approves First IHC Companion Diagnostic for Mirvetuximab Soravtansine in Ovarian Cancer
November 15th 2022The FDA has approved the VENTANA FOLR1 RxDx assay, the first immunohistochemistry companion diagnostic test to help identify patients with epithelial ovarian cancer who are eligible for treatment with mirvetuximab soravtansine-gynx.
Prostate Cancer Has High Rate of Actionable Mutations, Underscoring Need for Testing
All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications.
Genetic Testing Proves Significant in Identifying Somatic and Germline Mutations in Prostate Cancer
November 11th 2022As the role of genetic testing in clinical practice becomes more prevalent for patients with prostate cancer to identify mutations, physicians must consider a variety of factors to determine which patients are candidates for somatic and/or germline testing.
Neoantigen TCR T-cell Therapy Shows Early Proof-of-Concept in Solid Tumors
A personalized neoantigen-specific and off-the-shelf T cell receptor T-cell therapy utilized through CRISPR gene editing technology demonstrated feasibility and tolerability in 16 patients across multiple tumor types, according to first-in-human phase 1a findings.